-
-
-
-
-
-
-
FDA grants priority review to ifinatamab deruxtecan for lung cancer treatment
-
-
-
-
-
-
-
Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1
-
-
-
-
-
-
-
Merck presents new HIV drug trial data on weight and lipid effects
-
-
-
-
-
-
-
Merck (MRK) Granted FDA Priority Review for WINREVAIR to Update Label Based on Results From ZENITH Trial
-
-
-
-
-
-
-
Merck (MRK) Granted FDA Priority Review to Application for KEYTRUDA Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
-
-
-
-
-
-
-
Merck Announces Second-Quarter 2024 Financial Results
-
-
-
-
-
-
-
Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
-
15,434 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

